Welcome to Evaluate Discovery,
a round up of our most-read content this month.
Featured Report
2025 World Preview: Pharma Growth Steady Amid Turbulent Seas and Rising China
Have you downloaded your copy of the World Preview 2025 report? It’s our annual dive into the latest forecasts for the pharma market and if you’ve not read it yet, you can find it here. Featuring expert analysts and tonnes of data, it’s a must-read for anyone who needs to understand the direction of the market, from key players to top pipeline projects.
Featured On-Demand Webinar:
2025 World Preview: Turbulent Seas
Join our experts as they unpack the key insights from our annual World Preview report, exploring how evolving global tariffs, regulatory uncertainty, and pricing pressures are reshaping the pharmaceutical landscape and what you can do to stay ahead.
Scroll for more content
Resources
REPORT/E-BOOK
Oncology Forecasting: A Different Kind of Challenge
BLOG
Back from BIO: The Evolving Biotech Investment Landscape
New Online Training Available
Our new Time Series Trending online course is now available! Designed specifically for pharmaceutical forecasters, this course offers a practical and accessible way to deepen your understanding of trending techniques. Whether you’re building on a foundation or looking to sharpen your approach, you’ll gain the confidence to select and apply the most appropriate algorithms for your data with clarity and precision.
Upcoming Events
Pharma CI US
Content Hubs
Market movers: Top 10 gains and losses
Evaluate Pharma’s Event Analyzer delivers a daily round up of key events driving company valuations, detailing the previous day’s top 10 market gains and losses, and the share price movement of the top pharma companies. Aligned with the news driving share prices, Event Analyzer keeps you in touch with the latest market moves.
To receive daily and weekly alerts, get in touch
Top 10 gains (%) - ranked on change in share price.
Performance: Mon 30 Jun vs Mon 02 Jun
Excludes companies with a market cap. movement of less than US$35m & non-Japanese Asian companies.
| Rank | Company | Listed Currency | Share Price Change | Market Cap (US$m) | Market Cap Change |
|---|---|---|---|---|---|
| 1 | SanBio | JPY | +49% | 1555 | +477 |
| 2 | Vera Therapeutics | USD | +40% | 2024 | +579 |
| 3 | INmune Bio | USD | +35% | 165 | +43 |
| 4 | Liquidia Corporation | USD | +29% | 1442 | +322 |
| 5 | Zealand Pharma | DKK | +26% | 4675 | +818 |
| 6 | BioCryst Pharmaceuticals | USD | +15% | 2245 | +289 |
| 7 | United Therapeutics | USD | +15% | 14681 | +1861 |
| 8 | Avidity Biosciences | USD | +14% | 3998 | +499 |
| 9 | Olympus | JPY | +13% | 14059 | +1235 |
| 10 | ADMA Biologics | USD | +13% | 4877 | +544 |
Top 10 losses (%) - ranked on change in share price.
Performance: Mon 30 Jun vs Mon 02 Jun
Excludes companies with a market cap. movement of less than US$35m & non-Japanese Asian companies.
| Rank | Company | Listed Currency | Share Price Change | Market Cap (US$m) | Market Cap Change |
|---|---|---|---|---|---|
| 1 | Vor Biopharma | USD | -79% | 29 | -107 |
| 2 | Sera Prognostics | USD | -61% | 58 | -92 |
| 3 | AbCellera Biologics | USD | -41% | 639 | -439 |
| 4 | Bausch Health Companies | USD | -31% | 1656 | -732 |
| 5 | Insmed | USD | -28% | 13056 | -5848 |
| 6 | Lexicon Pharmaceuticals | USD | -25% | 226 | -75 |
| 7 | Ginkgo Bioworks Holdings | USD | -25% | 417 | -136 |
| 8 | CRISPR Therapeutics | USD | -22% | 3191 | -910 |
| 9 | BridgeBio Pharma | USD | -21% | 6733 | -1784 |
| 10 | ARS Pharmaceuticals | USD | -21% | 1420 | -367 |
Upcoming events & conferences
Featured Event
Pharma CI Europe
Conference | April 23-24
Munich, Germany
Evaluate will be speaking at the largest conference for pharmaceutical, biotechnology, medical device, and diagnostic competitive intelligence executives.
